PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Juric D, Song K, Johnson RM, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Gendreau S, Hwang MS, Kuang Z, Lau JT, Lin E, Pham T, Maddalo D, Rees MG, Ronan MM, Roth JA, Martin S, Sodir NM, Sokol ES, Whitfield ZJ, Wong A, Yauch RL, Aimi J, Cheeti S, Fredrickson J, Hilz S, Hafner M, Hutchinson KE, Jin Y, Peters U, Zingg D, Royer-Joo S, Shankar N, Schutzman JL, Jhaveri KL, Dey A

Open source

DOI
10.1158/1078-0432.ccr-25-1459
Published
2026 Jan 6
Container
Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-1459,
  title = {PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.},
  author = {Juric D and Song K and Johnson RM and Accordino MK and Bedard PL and Cervantes A and Gambardella V and Hamilton E and Italiano A and Kalinsky K and Krop IE and Oliveira M and Saura C and Schmid P and Turner NC and Varga A and Gendreau S and Hwang MS and Kuang Z and Lau JT and Lin E and Pham T and Maddalo D and Rees MG and Ronan MM and Roth JA and Martin S and Sodir NM and Sokol ES and Whitfield ZJ and Wong A and Yauch RL and Aimi J and Cheeti S and Fredrickson J and Hilz S and Hafner M and Hutchinson KE and Jin Y and Peters U and Zingg D and Royer-Joo S and Shankar N and Schutzman JL and Jhaveri KL and Dey A},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-1459},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-1459}
}

RIS

TY  - JOUR
TI  - PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
AU  - Juric D
AU  - Song K
AU  - Johnson RM
AU  - Accordino MK
AU  - Bedard PL
AU  - Cervantes A
AU  - Gambardella V
AU  - Hamilton E
AU  - Italiano A
AU  - Kalinsky K
AU  - Krop IE
AU  - Oliveira M
AU  - Saura C
AU  - Schmid P
AU  - Turner NC
AU  - Varga A
AU  - Gendreau S
AU  - Hwang MS
AU  - Kuang Z
AU  - Lau JT
AU  - Lin E
AU  - Pham T
AU  - Maddalo D
AU  - Rees MG
AU  - Ronan MM
AU  - Roth JA
AU  - Martin S
AU  - Sodir NM
AU  - Sokol ES
AU  - Whitfield ZJ
AU  - Wong A
AU  - Yauch RL
AU  - Aimi J
AU  - Cheeti S
AU  - Fredrickson J
AU  - Hilz S
AU  - Hafner M
AU  - Hutchinson KE
AU  - Jin Y
AU  - Peters U
AU  - Zingg D
AU  - Royer-Joo S
AU  - Shankar N
AU  - Schutzman JL
AU  - Jhaveri KL
AU  - Dey A
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-1459
UR  - https://doi.org/10.1158/1078-0432.ccr-25-1459
ER  -

APA

D, J., K, S., RM, J., MK, A., PL, B., A, C., V, G., E, H., A, I., K, K., IE, K., M, O., C, S., P, S., NC, T., A, V., S, G., MS, H., Z, K., JT, L., E, L., T, P., D, M., MG, R., MM, R., JA, R., S, M., NM, S., ES, S., ZJ, W., A, W., RL, Y., J, A., S, C., J, F., S, H., M, H., KE, H., Y, J., U, P., D, Z., S, R., N, S., JL, S., KL, J., & A, D. (2026). PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-1459

Source records